Antiretroviral therapy for HIV: Do subtypes matter?

Clinical Infectious Diseases

Volumn 53, Issue 11, 2011, Pages 1153-1155

  Gatell, José M ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; DARUNAVIR; EFAVIRENZ; ENFUVIRTIDE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RALTEGRAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ANTIVIRAL RESISTANCE; CAUCASIAN; DISEASE CLASSIFICATION; DISEASE TRANSMISSION; DRUG EFFICACY; DRUG EXPOSURE; ETHNICITY; GENETIC VARIABILITY; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NOTE; OUTCOME ASSESSMENT; PANDEMIC; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVERSE TRANSCRIPTION; SCIENTIFIC LITERATURE; TREATMENT RESPONSE; VIRAL GENETICS; VIRUS DETECTION; VIRUS STRAIN;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; VIRAL LOAD;

EID: 80755172432     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir686     Document Type: Note

References (30)

1. Geretti AM, Harrison L, Green H, et al. Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy. Clin Infect Dis 2009;48: 1296-305.
2. Kosakovsky Pond SL, Smith DM. Are all subtypes created equal? The effectiveness of antiretroviral therapy against non-subtype B HIV-1. Clin Infect Dis 2009;48:1306-9.
3. Scherrer AU, Ledergerber B, Von Vyl V, et al. Improved virological outcome in Caucasians infected with HIV-1 non-B subtypes compared with subtype B. Clin Infect Dis 2011;53:1143-52.
4. Bouchaud O, Le Moing V, Simon F, et al. Similar short-term efficacy of antiretroviral therapy in patients infected with HIV B and non-B subtype strains in France. J Acquir Immune Defic Syndr 2011;56:e67-9.
5. Bannister WP, Ruiz L, Loveday C, et al. HIV-1 subtypes and response to combination antiretroviral therapy in Europe. Antivir Ther 2006;11:707-15. (Pubitemid 44497166)
6. Alexander CS, Montessori V, Wynhoven B, et al. Prevalence and response to antiretroviral therapy of non-B subtypes of HIV in antiretroviral-naive individuals in British Columbia. Antivir Ther 2002;7:31-5. (Pubitemid 36285549)
7. Pillay D, Walker AS, Gibb DM, et al. Impact of human immunodeficiency virus type 1 subtypes on virologic response and emergence of drug resistance among children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 trial. J Infect Dis 2002;186:617-25. (Pubitemid 34925533)
8. Rockstroh JK, Teppler H, Zhao J, et al. Clinical efficacy of raltegravir against B and non-B subtype HIV-1 in phase III clinical studies. AIDS 2011;25:1365-9.
9. Lataillade M, Yang R, Mancini M, McGrath D, for the BMS AI424138 Study Group. Impact of HIV viral diversity and baseline resistance on treatment outcomes and the emergence of resistance: the CASTLE study 48-week results. Ninth International Congress on Drug Therapy in HIV Infection. November 9-13. Glasgow, United Kingdom: 2008.
10. Dierynck I, De MS, Lathouwers E, et al. In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-naive patients. Antivir Ther 2010;15:1161-9.
11. Taylor BS, Sobieszczyk ME, McCutchan FE, Hammer SM. The challenge of HIV-1 subtype diversity. N Engl J Med 2008;358: 1590-602.
12. Hemelaar J, Gouws E, Ghys PD, Osmanov S. Global trends in molecular epidemiology of HIV-1 during 2000-2007. AIDS 2011;25: 679-89.
13. Hemelaar J, Gouws E, Ghys PD, Osmanov S. Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS 2006;20:W13-23. (Pubitemid 44611051)
14. Salemi M. Toward a robust monitoring of HIV subtypes distribution worldwide. AIDS 2011;25:713-4.
15. Descamps D, Chaix ML, Montes B, et al. Increasing prevalence of transmitted drug resistance mutations and non-B subtype circulation in antiretroviral-naive chronically HIV-infected patients from 2001 to 2006/2007 in France. J Antimicrob Chemother 2010;65:2620-7.
16. Garcia F, Perez-Cachafeiro S, Guillot V, et al. Transmission of HIV drug resistance and non-B subtype distribution in the Spanish cohort of antiretroviral treatment naive HIV-infected individuals (CoRIS). Antivir Res 2011;91:150-3.
17. Wheeler WH, Ziebell RA, Zabina H, et al. Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U.S.-2006. AIDS 2010;24:1203-12.
18. Conroy SA, Laeyendecker O, Redd AD, et al. Changes in the distribution of HIV type 1 subtypes D and A in Rakai District, Uganda between 1994 and 2002. AIDS Res Hum Retrov 2010;26:1087-91.
19. Tovanabutra S, Robison V, Wongtrakul J, et al. Male viral load and heterosexual transmission of HIV-1 subtype E in northern Thailand. J Acquir Immune Defic Syndr 2002;29:275-83. (Pubitemid 34208536)
20. van de Vijver DA, Wensing AM, Angarano G, et al. The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes. J Acquir Immune Defic Syndr 2006;41:352-60.
21. Abecasis AB, Deforche K, Bacheler LT, et al. Investigation of baseline susceptibility to protease inhibitors in HIV-1 subtypes C, F, G and CRF02AG. Antivir Ther 2006;11:581-9. (Pubitemid 44277423)
22. Parkin NT, Schapiro JM. Antiretroviral drug resistance in non-subtype B HIV-1, HIV-2 and SIV. Antivir Ther 2004;9:3-12. (Pubitemid 38324510)
23. Invernizzi CF, Coutsinos D, Oliveira M, Moisi D, Brenner BG, Wainberg MA. Signature nucleotide polymorphisms at positions 64 and 65 in reverse transcriptase favor the selection of the K65R resistance mutation in HIV-1 subtype C. J Infect Dis 2009;200:1202-6.
24. Wainberg MA. HIV-1 subtype distribution and the problem of drug resistance. AIDS 2004;18(Suppl 3):S63-8. (Pubitemid 39037462)
25. Vergne L, Snoeck J, Aghokeng A, et al. Genotypic drug resistance interpretation algorithms display high levels of discordance when applied to non-B strains from HIV-1 naive and treated patients. FEMS Immunol Med Microbiol 2006;46:53-62.
26. Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010;304:321-33.
27. [National consensus document by GESIDA/National Aids Plan on antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2011 update)]. Enferm Infecc Microbiol Clin 2011;29:209:e1-e103.
28. EACS guidelines. Clinical management and treatment of HIV infected adults in Europe. 2011. Version 5. November, 2009. Available at: http:// europeanaidsclinicalsociety. org/. Accessed 25 July 2011.
29. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2011. Available at http://www.aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf. Accessed 25 July 2011.
30. EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. J Hepatol 2011;55:245-64.